MS
ADMS

Maven Securities’s Adamas Pharmaceuticals ADMS Stock Holding History

Maven Securities’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-250,000
Closed -$1.23M – 1499
2021
Q1 		$1.23M Buy
+250,000
New +$1.31M 0.05% 339

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Maven Securities's ADMS Position: Q2 2021 in Review

Maven Securities sold out of Adamas Pharmaceuticals (ADMS) in Q2 2021, closing a stake of 250,000 shares — an estimated $1.23M sold.

Maven Securities first reported a position in ADMS in Q1 2021 and held it in 1 quarter. The position peaked at $1.23M in Q1 2021. 67 funds tracked by Wall St. Rank hold ADMS as of Q2 2021.

  • Maven Securities reported no remaining Adamas Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 250,000 Adamas Pharmaceuticals shares in Q2 2021, an estimated $1.23M.
  • Maven Securities first reported a position in Adamas Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Maven Securities's Adamas Pharmaceuticals position peaked at $1.23M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.